Almac Announces Expansion to its Commercial Facility with the Addition of Increased Storage Capacity for Biologic Products
In response to increased client demand for cold and dedicated frozen storage capacity for biopharmaceuticals, Almac’s Pharma Services business unit has expanded its commercial facilities to include an additional 6,124 sq ft of cold and frozen storage.
This is a joint investment with a commercial client, for which Almac provides central EU importation, warehousing and distribution services. This includes dedicated -70°C, -20°C and 2-8°C storage for drug antibody, drug linker, bulk drug substance, placebo and filled vials, coupled to before and after distribution to various global processing facilities.
In preparation for the successful commercialisation of the drug product, 20 additional dedicated freezer units have been added to the existing 10, for the storage of the monoclonal antibody and bulk drug substance products.
Strengthening Almac’s EU product launch services, the expansion has also resulted in increased floor space facilitating shipping system configuration for bulk drug product and for direct to pharmacy supply of niche orphan drug products.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
